Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY SHAREHOLDERS' MEETING

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") announces that at its 2025 second extraordinary shareholders' meeting (the "**Shareholders' Meeting**") held on Wednesday, December 31, 2025, the resolution on the proposed amendments to the Articles of Association was duly passed by way of poll. The Shareholders' Meeting was convened by the board (the "**Board**") of directors of the Company (the "**Directors**").

Further details of the resolution are set out in the notice of the Shareholders' Meeting dated December 10, 2025 (the "**Notice**") and the circular of the Company dated the same date (the "**Circular**").

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record date for the Shareholders' Meeting, (i) the total number of the issued shares of the Company (the "**Shares**") was 6,637,199,874 Shares, comprising 258,197,600 H Shares and 6,379,002,274 A Shares; and (ii) holders of 6,633,460,924 Shares (or by authorized proxies) were entitled to attend and vote on the resolution proposed at the Shareholders' Meeting. The total number of Shares for calculating the attendance of the Shareholders' Meeting does not include the 3,738,950 A Shares repurchased and held in the stock repurchase account of the Company as treasury shares. The Company has not exercised the voting rights of the aforementioned Shares at the Shareholders' Meeting. In addition, there were no Shares repurchased by the Company which are pending cancellation.

To the best knowledge, information and belief of the Company, no Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolution proposed at the Shareholders' Meeting. Further, no party has stated any intention in the Circular to vote against or to abstain from voting on the resolution proposed at the Shareholders' Meeting, and there were no Shares entitling the Shareholder to attend and abstain from voting in favor of the resolution proposed at the Shareholders' Meeting as set out in Rule 13.40 of the Hong Kong Listing Rules.

ATTENDANCE AT THE SHAREHOLDERS' MEETING

The Board is pleased to announce that the Shareholders' Meeting was held on Wednesday, December 31, 2025 at 2:30 p.m. at No. 1288, Haike Road, Pudong New Area, Shanghai, PRC.

All Directors, supervisors of the Company and secretary to the Board attended the Shareholders' Meeting either in person or by electronic means.

Set out below are the details of the Shareholders and authorized proxies present at the Shareholders' Meeting:

Number of Shareholders and authorised proxies		3,521
Including:	Number of A Shareholders	3,520
	Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)		3,761,447,926
Including:	Total number of Shares carrying voting rights held by A Shareholders (shares)	3,612,743,654
	Total number of Shares carrying voting rights held by H Shareholders (shares)	148,704,272
Percentage of the total number of Shares carrying voting rights (%)		56.7041
Including:	Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	54.4624
	Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	2.2417

POLL RESULT OF THE SHAREHOLDERS' MEETING

The poll result of the Shareholders' Meeting was as follows:

Special Resolution		Number of votes cast (approximate percentage of total number of votes cast)			Passed by Shareholders
		For	Against	Abstain	
1	To consider and approve the proposed amendments to the Articles of Association	3,759,502,108 (99.9483%)	1,083,793 (0.0288%)	862,025 (0.0229%)	Yes

Notes:

(1) Please refer to the Notice and Circular for details of the resolution.

(2) All percentages are rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.

(3) A special resolution is passed by more than two-thirds of the votes casted in favor of it.

SCRUTINY OF VOTE-COUNTING AND LAWYER'S CERTIFICATION

Pursuant to the Hong Kong Listing Rules, Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of H Shares at the Shareholders' Meeting.

Grandall Law Firm (Nanjing) witnessed the Shareholders' Meeting and certified that the convening and holding procedures, qualification of the attendees and convenor as well as voting procedures and voting results of the Shareholders' Meeting conformed to the requirements of the relevant PRC laws, rules and regulations, guidelines, and the Articles of Association of the Company. The voting result was lawful and valid.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
December 31, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.